The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $63,239,785.00 definitive contract to Arcturus Therapeutics, Inc. for the procurement of a pandemic influenza vaccine (PandFlu) and a quadrivalent seasonal influenza vaccine (QsFlu). This contract is not a set-aside and supports the Arcturus self-amplifying mRNA-based vaccine platform for rapid pandemic influenza response, a key priority under ASPR's Biomedical Advanced Research and Development Authority (BARDA) program. The award stems from a BARDA Broad Agency Announcement that sought proposals for the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. The contract has an ultimate completion date of August 20, 2026.
Generated 11/9/24, 9:09 AM